• 1
    Tandon R. Safety and tolerability: how do newer generation ‘atypical’ antipsychotics compare? Psychiatric Q 2002;73: 297311.
  • 2
    Basile VS, Masellis M, McIntyre RS et al. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001;62(Suppl. 23):4566.
  • 3
    Ackerman S, Nolan LJ. Bodyweight gain induced by psychotropic drugs. Incidence, mechanisms and management. CNS Drugs 1998;9: 135151.
  • 4
    Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999;100: 316.
  • 5
    Baptista T, Kin N, Beaulieu S et al. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002;35: 205219.
  • 6
    Sussman N. Choosing a typical antipsychotic. Int Clin Psychopharmacol 2002;17(Suppl. 3):S29S33.
  • 7
    Wetterling T, Müßigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999;19: 316321.
  • 8
    Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999;60(Suppl. 21):2024.
  • 9
    Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 16861696.
  • 10
    Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62(Suppl. 23):512.
  • 11
    Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Safety 2001;24: 5973.
  • 12
    Wirshing DA, Erhart SM, Pierre JM et al. Nonextrapyramidal side effects of novel antipsychotics. Curr Opin Psychiatry 2000;13: 4550.
  • 13
    Green AI, Patel JK, Goisman RM et al. Weight gain from novel antipsychotic drugs: need for action. General Hosp Psychiatry 2000;22: 224235.
  • 14
    Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry 2002;63 (Suppl. 9):511.
  • 15
    Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. Schizophr Bull 1996;22: 413430.
  • 16
    Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophrenia Bull 1995;21: 463472.
  • 17
    Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophrenia Bull 2002;28: 4361.
  • 18
    Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry 2001;46: 549555.
  • 19
    Theisen FM, Linden A, Geller F et al. Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relation to antipsychotic medication. J Psychiatr Res 2001;35: 339345.
  • 20
    Aquila R. Management of weight gain in patients with schizophrenia. J Clin Psychiatry 2002;63(Suppl. 4):3336.
  • 21
    National Heart, Lung, and Blood Institute. First Federal Obesity Clinical Guidelines. NIH News Release, June 17 1998. Bethesda, MD: NHLBI, 1998.
  • 22
    Stedman T, Welman J. The distribution of adipose tissue in female in-patients receiving psychotropic drugs. Br J Psychiatry 1993;162: 249250.
  • 23
    Sharpe JK, Hills AP. Anthrometry and adiposity in a group of people with chronic mental illness. Aus NZ J Psychiatry 1998;32: 7781.
  • 24
    Lapidus L, Bengtsson C, Larsson B et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of Gothenburg, Sweden. Br Med J 1984;289: 12571261.
  • 25
    Ananth J, Burgoyne K, Gadasally R. Comparison of weight gain associated with three atypical antipsychotic drugs and haloperidol. Int J Neuropsychopharmacol 2000;3(Suppl. 1):S163.
  • 26
    Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158: 765774.
  • 27
    Beasley CM. Safety of olanzapine. J Clin Psychiatry Monogr 1997;15: 1921.
  • 28
    Barak Y. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J Clin Psychiatry 2002;63: 117119.
  • 29
    Gomez JC, Sacristan JA, Hernandez J et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J Clin Psychiatry 2000;61: 335343.
  • 30
    Ganguli R, Brar JS, Ayrton Z. Weight gain over 4 months in schizophrenia patients. a comparison of olanzapine and risperidone. Schizophrenia Res 2001; 49: 261267.
  • 31
    Taylor DM, McAskill R. Atypical antipsychotics and weight gain – a systematic review. Acta Psychiatr Scand 2000;101: 416432.
  • 32
    Patil KB. Comparative Weight Change with Atypical Antipsychotic Treatment. Presented at the American Psychiatric Association 2001 Annual Meeting, 5–10 May 2001, New Orleans, LA. Washington, DC: American Psychiatric Association, 2001.
  • 33
    Simpson MM, Goetz RR, Devlin MJ et al. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. J Clin Psychiatry 2001;62: 694700.
  • 34
    Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain,and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157: 975981.
  • 35
    Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002;16: 7789.
  • 36
    Kinon BJ, Milton DR, Gilmore JA. Continued improvement in quality of life despite weight change during olanzapine treatment. Int J Neuropsychopharmacol 2000;3(Suppl. 1):S154.
  • 37
    Wirshing DA, Wirshing WC, Kysar L et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60: 358363.
  • 38
    Casey DE, Zorn Sh. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 2001;62(Suppl. 7):410.
  • 39
    Seeman P, Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA 2000;97: 73637365.
  • 40
    Eliosoff RV. The obese patient: are drugs an option? Can J Diagnosis 1997;14: 7994.
  • 41
    Fujisawa T, Ikegami H, Yamato E et al. Association of Trp64Arg mutation of the β3-adrenergic-receptor with NIDDM and body weight gain. Diabetologia 1996;39: 349352.
  • 42
    Schotte A, Janssen PF M, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124: 5773.
  • 43
    Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999;130: 671680.
  • 44
    Kraus T, Haack M, Schuld A et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999;156: 312314.
  • 45
    Atmaca M, Kuloglu M, Tezcan E et al. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol[letter]. Schizophrenia Res 2003;60: 99100.
  • 46
    Herrán A, García-Unzueta MT, Amado JT et al. Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 2001;179: 5962.
  • 47
    Reaven GM. Role of insulin resistance in human disease. Diabetes 1986;37: 15951607.
  • 48
    Newcomer JW, Haupt DW, Fucetola R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch General Psychiatry 2002;59: 337345.
  • 49
    Cohn TA, Remington G, Lieter L, Kameh H. Antipsychotic Medication and Insulin Resistance. Abstract NR555. Presented at the American Psychiatric Association 2001 Annual Meeting, 5–10 May 2001, New Orleans, LA. Washington, DC: American Psychiatric Association, 2001.
  • 50
    Baptista T. Atypical antipsychotic drugs and glucose dysregulation[letter]. Can J Psychiatry 2002;47: 9496.
  • 51
    Lean M. Clinical Handbook of Weight Management. London: Martin Dunitz, 1998.
  • 52
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348: 16251638.
  • 53
    Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177: 212217.
  • 54
    Ryan MCM, Thakore JH. Physical consequences of schizophrenia and its treatment. The metabolic syndrome. Life Sci 2002;71: 239257.
  • 55
    Brown S, Birtwistle J, Roe L et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29: 697701.
  • 56
    Henderson DC, Ettinger ER. Schizophrenia and diabetes. Int Rev Neurobiol 2002;51: 481501.
  • 57
    McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46: 273281.
  • 58
    Gianfrancesco F, Grogg AL, Mahmoud RA et al. Differential effects of risperidone, olanzapine, cloza- pine and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63: 920930.
  • 59
    Caro J, Ward A, Levinton C et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002;63: 11351139.
  • 60
    Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Europ Neuropsychopharmacol 2001;11: 2532.
  • 61
    Iqbal N, Oldan RL, Baird G et al. Diabetes Mellitus Induced by Atypical Antipsychotics. Presented at the 59th American Psychiatric Association Institute on Psychiatric Services, October 25–29, 2000, Philadelphia.
  • 62
    Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001;16: 6374.
  • 63
    Ananth J, Venkatesh R, Burgoyne K et al. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002;71: 244254.
  • 64
    Hedenmalm K, Hägg S, Ståhl M et al. Glucose intolerance with atypical antipsychotics. Drug Safety 2002;25: 11071116.
  • 65
    Henderson DC. Atypical antipsychotic-induced diabetes mellitus. How strong is the evidence? CNS Drugs 2002; 16: 7789.
  • 66
    Koro CE, Fedder DO, L'Italien GJ et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 2002;325: 243245.
  • 67
    Lindenmayer J-P, Nathan A-M, Smith RC. Hyperglycaemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62(Suppl. 23):3038.
  • 68
    Jin H, Meyer JM, Veste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics. an analysis of 45 published cases. Ann Clin Psychiatry 2002;14: 5964.
  • 69
    Lindenmayer J-P, Czobor P, Volavka J et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160: 290296.
  • 70
    Kato MM, Goodnick PJ. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother 2001;2: 15711582.
  • 71
    Wilson DR, D'Souza L, Sarkar N et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophrenia Res 2002;59: 16.
  • 72
    Domon SE, Cargile CS. Quetiapine-associated hyperglycaemia and hypertriglyceridemia[letter]. J Am Acad Child Adolesc Psychiatry 2002;41: 495496.
  • 73
    Bouchard RH, Demers M-F, Simoneau I et al. Atypical antipsychotics and cardiovascular risk in schizophrenic patients[letter]. J Clin Psychopharmacol 2001;21: 110111.
  • 74
    Procyshyn RM, Kennedy NB, Marriage S et al. Plasma protein and lipoprotein distribution of clozapine. Am J Psychiatry 2001;158: 949951.
  • 75
    Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001;62 (Suppl. 27):2734.
  • 76
    Koro CE, Fedder DO, L'Italien GJ et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59: 10211026.
  • 77
    Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002;63: 425433.
  • 78
    Chue P, Welch R. Investigation of the Metabolic Effects of Antipsychotics in Patients with Schizophrenia. Presented at the 51st Annual Meeting of the Canadian Psychiatric Association, November 15–19, 2001, Montreal, Canada.
  • 79
    Martin A, L'Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Europ Child Adolesc Psychiatry 2002;11: 129133.
  • 80
    Kawachi I. Physical and psychological consequences of weight gain. J Clin Psychiatry 1999;60(Suppl. 21):59.
  • 81
    Kurtzhaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001;62(Suppl. 7):3237.
  • 82
    Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003;54: 565567.
  • 83
    Perkins DO. Adherence to antipsychotic medication. J Clin Psychiatry 1999;60(Suppl. 21):2530.
  • 84
    Perkins DO. Predictors of non-compliance inpatients with schizophrenia. J Clin Psychiatry 2002;63: 11211128.
  • 85
    Fleischhacker WW, Meise U, Günther V et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994;89(Suppl. 382):1115.
  • 86
    National Schizophrenia Fellowship. A Question of Choice. Available at London: NSF, 2000.
  • 87
    Buis W. Patients' opinions concerning side effects of depot neuroleptics. Am J Psychiatry 1992;149: 844845.
  • 88
    Fakhouri W. Extent of distress caused by adverse experiences associated with antipsychotic treatment. J Eur Coll Neuropsychopharmacol 1999;9: S285.
  • 89
    Weiden PJ, Mackell J, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. J Eur Coll Neuropsychopharmacol 2000;10(Suppl. 3):S289.
  • 90
    Sachs GS, Guille C. Weight gain associated with use of psychotic medications. J Clin Psychiatry 1999;60: 1619.
  • 91
    Allison DB, Mackell J. Healthcare resource use and body mass index among individuals with schizophrenia. Int J Neuropsychopharmacol 2000;3(Suppl. 1):S124.
  • 92
    Weiden PJ, Mackell JA, McDonnell DD. Recent weight gain and the cost of acute service use among individuals with schizophrenia. J Eur Coll Neuropsychopharmacol 2001;11: S271.
  • 93
    Fontaine KR, Barofsky I, Andersen RE et al. Impact of weight loss on health-related quality of life. Qual Life Res 1999;8: 275277.
  • 94
    Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry 1999;60(Suppl. 21):3136.
  • 95
    Blackburn GL. Weight gain and antipsychotic medication. J Clin Psychiatry 2000;61(Suppl. 8):3641.
  • 96
    Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv 2001;52: 967969.
  • 97
    Littrell Kh, Petty RG, Hilligoss NM et al. Educational Interventions for the Management of Antipsychotic-Related Weight Gain. Abstract NR244. Presented at the American Psychiatric Association Annual Meeting, 5–10 May, 2001, New Orleans, LA. Washington, DC: American Psychiatric Association, 2001.
  • 98
    Cohn T, Miles J, Blake J et al. A Novel Weight Management Program for Young Adults at Risk for Antipsychotic-induced Weight Gain. Presented at the XXIInd CINP Congress, July 9–23 2000, Brussels, Belgium.
  • 99
    Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Europ Neuropsychopharmacol 2001;11: 181182.
  • 100
    Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB, Nizatidine for prevention of weight gain with olazapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003;13: 8185.